Lakewood-Amedex Biotherapeutics Operating Income

As of the most recent data (June 2026), LABT shows a operating income of $-7.3M. That compares with $-3M in the prior-year period — down 146.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LABT's operating income is now $-7.3M (was $-3M) — a 146.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lakewood-Amedex Biotherapeutics is outperforming or lagging.

Tracking LABT's operating income over time shows whether Lakewood-Amedex Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-7.3M That compares with $-3M in the prior-year period — down 146.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Lakewood-Amedex Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-7.3M) with ownership activity and broader fundamentals.

Lakewood-Amedex Biotherapeutics's operating income is $-7.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.